Wenwei Lin

Wenwei Lin is a Principal HTS Scientist at St. Jude Children's Research Hospital since December 2017, notable for the discovery of the first human pregnane X receptor antagonist with potential applications in enhancing chemotherapeutic efficacy and reducing adverse drug interactions. Prior roles at St. Jude include HTS Specialist and Senior HTS Technologist, contributing to advancements in high-throughput screening methodologies. Earlier experience as a Junior Researcher at the Chinese Academy of Medical Sciences involved isolating and characterizing key chemical components from herbal sources for potential medicinal applications. Wenwei Lin holds a Doctor of Philosophy in Pharmaceutical Sciences, a Master of Science in Medicinal Chemistry, and a Bachelor of Science in Medicinal Chemistry, complemented by a postdoctoral research associate position in Chemical Biology and Therapeutics at St. Jude.